MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Thumbnail Image Read more about MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion
Kura Oncology Receives Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML Thumbnail Image Read more about Kura Oncology Receives Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML
Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program Thumbnail Image Read more about Rgenta Therapeutics Joins The Leukemia & Lymphoma Society Therapy Acceleration Program
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study Thumbnail Image Read more about MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma Thumbnail Image Read more about Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma
Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies Thumbnail Image Read more about Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction Thumbnail Image Read more about MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Vittoria Biotherapeutics Announces the Presentation of New Data Supporting the Company's Platform at the 65th American Society of Hematology Annual Meeting Thumbnail Image Read more about Vittoria Biotherapeutics Announces the Presentation of New Data Supporting the Company's Platform at the 65th American Society of Hematology Annual Meeting
Immunitas Therapeutics Announces Upcoming Presentation at ASH 2023 Annual Meeting Thumbnail Image Read more about Immunitas Therapeutics Announces Upcoming Presentation at ASH 2023 Annual Meeting
Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Rare Blood Cancers at ASH 2023 Thumbnail Image Read more about Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Rare Blood Cancers at ASH 2023
